Ayvens SA (AYV) AI Stock Analysis

• Market Cap: €7.97B
• Dividend Yield: 3.77%
• Average Volume (3M): 359.00K
• Price to Earnings (P/E): 10.0
• Beta (1Y): 1.42
• Revenue Growth: 5.22%
• EPS Growth: 35.25%
• Country: FR
• Employees: 13,092
• Sector: Industrials
• Sector Strength: 83
• Industry: Rental & Leasing Services
• EPS (TTM): 0.30
• Shares Outstanding: 816,960,450
• 10 Day Avg. Volume: 268,627
• 30 Day Avg. Volume: 359,000
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €10.83
• Price Target Upside: 9.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 67 Neutral
• Price Target: €10.50 ▲(6.06% Upside)

Ayvens SA's overall stock score reflects a mix of strong technical indicators and attractive valuation, offset by financial performance challenges. The bullish trend in technical analysis and low P/E ratio suggest potential upside, while financial performance highlights the need for improved profitability and leverage management.

Ayvens SA Business Overview & Revenue Model

Company Description

Ayvens SA (AYV) is a technology-driven company specializing in innovative solutions for the healthcare and wellness sectors. The company focuses on developing advanced software applications and digital platforms that enhance patient care, streamline healthcare operations, and improve overall health outcomes. With a commitment to leveraging cutting-edge technology, Ayvens SA offers products such as telemedicine platforms, health monitoring systems, and data analytics tools designed for healthcare providers and patients alike.

How the Company Makes Money

Ayvens SA generates revenue through a multi-faceted business model that includes subscription-based services, software licensing, and consulting fees. The primary revenue streams consist of subscription fees from healthcare providers for access to their telemedicine platform and data analytics services, which are charged monthly or annually. Additionally, the company earns income from licensing its proprietary technology to other businesses in the healthcare sector. Significant partnerships with healthcare organizations and technology firms enhance Ayvens SA's market reach and capabilities, allowing for collaborative product development and expanded service offerings, which contribute to its overall earnings.

Ayvens SA Financial Statement Overview

Summary

ALD SA demonstrates robust revenue growth and operational efficiency, but faces challenges with profitability volatility and high leverage. Cash flow management issues persist due to substantial capital expenditures.

Income Statement

ALD SA showed strong revenue growth, with a significant increase in total revenue over the years. However, the gross and net profit margins have been fluctuating, which indicates some instability in profitability. The EBIT and EBITDA margins are decent, reflecting good operational efficiency despite the volatility in net income.

Balance Sheet

The company has a high debt-to-equity ratio, which suggests potential risk due to significant leverage. However, the return on equity has been relatively strong, indicating efficient use of shareholder capital. The equity ratio is low, pointing to a low proportion of equity financing in the asset base.

Cash Flow

ALD SA's cash flow situation is challenging, with negative free cash flow throughout the years. While operating cash flow has been positive in most years, the high capital expenditures have resulted in negative free cash flow, impacting the company's ability to generate cash internally.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	25.35B	18.74B	11.37B	10.44B	9.86B
Gross Profit	2.98B	2.80B	2.20B	1.44B	984.00M
EBITDA	1.25B	7.62B	5.55B	5.03B	4.67B
Net Income	683.60M	816.20M	1.22B	873.00M	509.80M
Balance Sheet
Total Assets	150.23B	70.26B	31.30B	26.99B	25.07B
Cash, Cash Equivalents and Short-Term Investments	5.43B	4.66B	584.70M	533.40M	545.10M
Total Debt	40.14B	37.88B	19.99B	18.64B	17.78B
Total Liabilities	139.07B	58.91B	24.39B	22.15B	20.87B
Stockholders Equity	11.13B	10.83B	6.88B	4.81B	4.16B
Cash Flow
Free Cash Flow	-11.00B	-3.27B	-4.71B	-3.78B	-2.56B
Operating Cash Flow	10.80B	-2.99B	4.95B	5.08B	4.71B
Investing Cash Flow	-12.24B	754.50M	-6.62B	-5.57B	-3.97B
Financing Cash Flow	2.23B	5.71B	1.97B	537.90M	-737.90M

Ayvens SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AYV, the sentiment is Positive. The current price of 9.9 is above the 20-day moving average (MA) of 9.68, above the 50-day MA of 9.49, and above the 200-day MA of 7.90, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 59.11 is Neutral, neither overbought nor oversold. The STOCH value of 40.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AYV.

Ayvens SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ELIS	79 Outperform	$6.03B	16.18	10.25%	1.76%	4.83%	52.47%
RXL	75 Outperform	€8.30B	33.46	4.63%	4.33%	2.16%	-64.02%
FGR	74 Outperform	€12.17B	11.35	15.80%	3.75%	7.37%	3.85%
Sector *	71 Outperform	¥269.83B	15.10	8.31%	2.77%	6.08%	11.04%
AYV	67 Neutral	€7.97B	9.99	7.26%	3.77%	5.22%	35.25%
SPIE	66 Neutral	€8.93B	43.97	10.66%	1.88%	10.87%	-10.35%
ALO	62 Neutral	€10.05B	70.14	1.54%	1.24%	4.94%	―